171 related articles for article (PubMed ID: 29782783)
1. Posterior Reversible Encephalopathy Syndrome (PRES) Presenting as Status Epilepticus: A Case Report and Literature Review.
Sharma P; Abbas MK; Huynh M
Conn Med; 2016 Sep; 80(8):475-478. PubMed ID: 29782783
[TBL] [Abstract][Full Text] [Related]
2. Fatal posterior revesible leukoencephalopathy syndrome associated coma induced by bevacizumab in metastatic colorectal cancer and review of literature.
Eryılmaz MK; Mutlu H; Salim DK; Musri FY; Coşkun HŞ
J Oncol Pharm Pract; 2016 Dec; 22(6):806-810. PubMed ID: 26467267
[TBL] [Abstract][Full Text] [Related]
3. Posterior reversible encephalopathy syndrome following chemotherapy with oxaliplatin and a fluoropyrimidine: a case report and literature review.
Femia G; Hardy TA; Spies JM; Horvath LG
Asia Pac J Clin Oncol; 2012 Jun; 8(2):115-22. PubMed ID: 22524570
[TBL] [Abstract][Full Text] [Related]
4. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis.
Martin RC; Scoggins CR; Schreeder M; Rilling WS; Laing CJ; Tatum CM; Kelly LR; Garcia-Monaco RD; Sharma VR; Crocenzi TS; Strasberg SM
Cancer; 2015 Oct; 121(20):3649-58. PubMed ID: 26149602
[TBL] [Abstract][Full Text] [Related]
5. Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.
Bendell JC; Tournigand C; Swieboda-Sadlej A; Barone C; Wainberg ZA; Kim JG; Pericay C; Pastorelli D; Tarazi J; Rosbrook B; Bloom J; Ricart AD; Kim S; Sobrero AF
Clin Colorectal Cancer; 2013 Dec; 12(4):239-47. PubMed ID: 24188685
[TBL] [Abstract][Full Text] [Related]
6. Fatal outcome of posterior "reversible" encephalopathy syndrome in metastatic colorectal carcinoma after irinotecan and fluoropyrimidine chemotherapy regimen.
Dedić Plavetić N; Rakušić Z; Ozretić D; Simetić L; Krpan AM; Bišof V
World J Surg Oncol; 2014 Aug; 12():264. PubMed ID: 25142792
[TBL] [Abstract][Full Text] [Related]
7. Posterior Reversible Encephalopathy Syndrome after a Variety of Combined Chemotherapies Containing Bevacizumab for Metastatic Colon Cancer.
Katada E; Mitsui A; Sasaki S; Uematsu N; Anan C
Intern Med; 2018 Aug; 57(16):2403-2407. PubMed ID: 29526944
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of bevacizumab with modified OPTIMOX1 as first-line therapy for metastatic colorectal cancer: the TCOG-GI 0802 study.
Nakayama N; Sato A; Tanaka S; Shimada K; Konishi K; Sasaki E; Hibi K; Ichikawa H; Kikuchi Y; Sakuyama T; Sekikawa T; Hayashi K; Nishina H;
Invest New Drugs; 2015 Aug; 33(4):954-62. PubMed ID: 25937430
[TBL] [Abstract][Full Text] [Related]
9. [Posterior Reversible Encephalopathy Syndrome (PRES): About 4 cases].
Chanal E; Bouleftour W; Rivoirard R; Bosaki C; Forges F; Jacquin JP; Fournel P; Mery B; Saban-Roche L
Presse Med; 2019 Oct; 48(10):1026-1031. PubMed ID: 31653541
[No Abstract] [Full Text] [Related]
10. Observational Cohort Study of Patients With Metastatic Colorectal Cancer Initiating Chemotherapy in Combination With Bevacizumab (CONCERT).
Bennouna J; Phelip JM; André T; Asselain B; Sébastien Koné ; Ducreux M
Clin Colorectal Cancer; 2017 Jun; 16(2):129-140.e4. PubMed ID: 28277294
[TBL] [Abstract][Full Text] [Related]
11. A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme).
Avallone A; Piccirillo MC; Aloj L; Nasti G; Delrio P; Izzo F; Di Gennaro E; Tatangelo F; Granata V; Cavalcanti E; Maiolino P; Bianco F; Aprea P; De Bellis M; Pecori B; Rosati G; Carlomagno C; Bertolini A; Gallo C; Romano C; Leone A; Caracò C; de Lutio di Castelguidone E; Daniele G; Catalano O; Botti G; Petrillo A; Romano GM; Iaffaioli VR; Lastoria S; Perrone F; Budillon A
BMC Cancer; 2016 Feb; 16():69. PubMed ID: 26857924
[TBL] [Abstract][Full Text] [Related]
12. Posterior Reversible Encephalopathy Syndrome in Patients With Cancer.
Singer S; Grommes C; Reiner AS; Rosenblum MK; DeAngelis LM
Oncologist; 2015 Jul; 20(7):806-11. PubMed ID: 26032137
[TBL] [Abstract][Full Text] [Related]
13. Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: a randomized phase 2 study.
Infante JR; Reid TR; Cohn AL; Edenfield WJ; Cescon TP; Hamm JT; Malik IA; Rado TA; McGee PJ; Richards DA; Tarazi J; Rosbrook B; Kim S; Cartwright TH
Cancer; 2013 Jul; 119(14):2555-63. PubMed ID: 23605883
[TBL] [Abstract][Full Text] [Related]
14. Delayed reversible posterior encephalopathy syndrome following chemotherapy with oxaliplatin.
Sharief U; Perry DJ
Clin Colorectal Cancer; 2009 Jul; 8(3):163-5. PubMed ID: 19632931
[TBL] [Abstract][Full Text] [Related]
15. Recurrent status epilepticus in posterior reversible encephalopathy syndrome as initial feature of pediatric lupus: A newly diagnosed case and literature review.
Nasri A; Bedoui I; Mrissa R; Riahi A; Derbali H; Zaouali J; Messelmani M; Mansour M
Brain Dev; 2016 Oct; 38(9):835-41. PubMed ID: 27068876
[TBL] [Abstract][Full Text] [Related]
16. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Venook AP; Niedzwiecki D; Lenz HJ; Innocenti F; Fruth B; Meyerhardt JA; Schrag D; Greene C; O'Neil BH; Atkins JN; Berry S; Polite BN; O'Reilly EM; Goldberg RM; Hochster HS; Schilsky RL; Bertagnolli MM; El-Khoueiry AB; Watson P; Benson AB; Mulkerin DL; Mayer RJ; Blanke C
JAMA; 2017 Jun; 317(23):2392-2401. PubMed ID: 28632865
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.
Cassidy J; Clarke S; Díaz-Rubio E; Scheithauer W; Figer A; Wong R; Koski S; Lichinitser M; Yang TS; Rivera F; Couture F; Sirzén F; Saltz L
J Clin Oncol; 2008 Apr; 26(12):2006-12. PubMed ID: 18421053
[TBL] [Abstract][Full Text] [Related]
18. [Clinical significance of bolus 5-fluorouracil for recurrent or metastatic colorectal cancer treated with FOLFOX+ BevacizumabTherapy].
Yoshida Y; Hasegawa J; Nishimura J; Hirota M; Kim Y; Nezu R
Gan To Kagaku Ryoho; 2011 Aug; 38(8):1293-6. PubMed ID: 21829066
[TBL] [Abstract][Full Text] [Related]
19. Posterior reversible encephalopathy syndrome: 'a headache' on the AMU.
Desai P; Bholah MH; Dunn E
Acute Med; 2013; 12(1):26-9. PubMed ID: 23539373
[TBL] [Abstract][Full Text] [Related]
20. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
Yamada Y; Takahari D; Matsumoto H; Baba H; Nakamura M; Yoshida K; Yoshida M; Iwamoto S; Shimada K; Komatsu Y; Sasaki Y; Satoh T; Takahashi K; Mishima H; Muro K; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K
Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
